nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Cytarabine—Gemcitabine—lung cancer	0.369	0.513	CrCrCtD
Regadenoson—Azacitidine—Gemcitabine—lung cancer	0.35	0.487	CrCrCtD
Regadenoson—Adenosine monophosphate—ADCY1—lung cancer	0.00205	0.195	CrCbGaD
Regadenoson—Adenosine triphosphate—ADCY1—lung cancer	0.00178	0.169	CrCbGaD
Regadenoson—Clofarabine—RRM1—lung cancer	0.00163	0.154	CrCbGaD
Regadenoson—Fludarabine—RRM1—lung cancer	0.00158	0.149	CrCbGaD
Regadenoson—Cladribine—RRM1—lung cancer	0.000935	0.0886	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—ABCG2—lung cancer	0.000814	0.0486	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—FLT1—lung cancer	0.000689	0.0411	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ALK—lung cancer	0.000619	0.0587	CrCbGaD
Regadenoson—ADORA2A—GPCRs, Other—GRM8—lung cancer	0.000534	0.0319	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GIPR—lung cancer	0.000491	0.0293	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—AKT1—lung cancer	0.000484	0.0458	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—lung cancer	0.000477	0.0452	CrCbGaD
Regadenoson—Clofarabine—ABCG2—lung cancer	0.000415	0.0394	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—KDR—lung cancer	0.000398	0.0237	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—KMT2A—lung cancer	0.000374	0.0223	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TOP1—lung cancer	0.000342	0.0204	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—CREBBP—lung cancer	0.00034	0.0203	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NKX2-1—lung cancer	0.000333	0.0199	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—GNG11—lung cancer	0.000322	0.0192	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—DUSP3—lung cancer	0.000299	0.0178	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—ADCY1—lung cancer	0.000289	0.0173	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—PTHLH—lung cancer	0.000269	0.016	CbGpPWpGaD
Regadenoson—S-Adenosylmethionine—CYP2E1—lung cancer	0.000261	0.0247	CrCbGaD
Regadenoson—Cladribine—ABCG2—lung cancer	0.000239	0.0226	CrCbGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—EP300—lung cancer	0.000231	0.0138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—DUSP3—lung cancer	0.00023	0.0137	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—AHR—lung cancer	0.00022	0.0132	CbGpPWpGaD
Regadenoson—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—lung cancer	0.000219	0.0131	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Irinotecan—lung cancer	0.000198	0.000781	CcSEcCtD
Regadenoson—Hypertension—Paclitaxel—lung cancer	0.000198	0.000781	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000198	0.00078	CcSEcCtD
Regadenoson—Discomfort—Etoposide—lung cancer	0.000197	0.000776	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—ADCY1—lung cancer	0.000196	0.0117	CbGpPWpGaD
Regadenoson—Pain—Irinotecan—lung cancer	0.000196	0.000774	CcSEcCtD
Regadenoson—Mental disorder—Docetaxel—lung cancer	0.000196	0.000772	CcSEcCtD
Regadenoson—Chest pain—Paclitaxel—lung cancer	0.000195	0.00077	CcSEcCtD
Regadenoson—Myalgia—Paclitaxel—lung cancer	0.000195	0.00077	CcSEcCtD
Regadenoson—Arthralgia—Paclitaxel—lung cancer	0.000195	0.00077	CcSEcCtD
Regadenoson—Hypotension—Cisplatin—lung cancer	0.000195	0.000768	CcSEcCtD
Regadenoson—Anxiety—Paclitaxel—lung cancer	0.000194	0.000767	CcSEcCtD
Regadenoson—Erythema—Docetaxel—lung cancer	0.000194	0.000767	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000194	0.000765	CcSEcCtD
Regadenoson—Nausea—Topotecan—lung cancer	0.000193	0.000762	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000193	0.000761	CcSEcCtD
Regadenoson—Discomfort—Paclitaxel—lung cancer	0.000193	0.000761	CcSEcCtD
Regadenoson—Abdominal discomfort—Methotrexate—lung cancer	0.000193	0.00076	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ADCY1—lung cancer	0.000193	0.0115	CbGpPWpGaD
Regadenoson—Cardiac arrest—Doxorubicin—lung cancer	0.000191	0.000755	CcSEcCtD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—OXTR—lung cancer	0.000191	0.0114	CbGpPWpGaD
Regadenoson—Pain—Gemcitabine—lung cancer	0.000191	0.000754	CcSEcCtD
Regadenoson—Nausea—Erlotinib—lung cancer	0.000191	0.000754	CcSEcCtD
Regadenoson—Anaphylactic shock—Etoposide—lung cancer	0.000191	0.000753	CcSEcCtD
Regadenoson—Diarrhoea—Vinorelbine—lung cancer	0.00019	0.000751	CcSEcCtD
Regadenoson—Dysgeusia—Docetaxel—lung cancer	0.00019	0.000751	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Cisplatin—lung cancer	0.00019	0.000749	CcSEcCtD
Regadenoson—Feeling abnormal—Irinotecan—lung cancer	0.000189	0.000746	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PPP2R1B—lung cancer	0.000188	0.0112	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Irinotecan—lung cancer	0.000188	0.00074	CcSEcCtD
Regadenoson—Anaphylactic shock—Paclitaxel—lung cancer	0.000187	0.000738	CcSEcCtD
Regadenoson—Paraesthesia—Cisplatin—lung cancer	0.000187	0.000738	CcSEcCtD
Regadenoson—ADORA2A—G alpha (s) signalling events—AVP—lung cancer	0.000186	0.0111	CbGpPWpGaD
Regadenoson—Tachycardia—Etoposide—lung cancer	0.000186	0.000735	CcSEcCtD
Regadenoson—Dyspnoea—Cisplatin—lung cancer	0.000186	0.000733	CcSEcCtD
Regadenoson—Skin disorder—Etoposide—lung cancer	0.000185	0.000731	CcSEcCtD
Regadenoson—Hyperhidrosis—Etoposide—lung cancer	0.000184	0.000728	CcSEcCtD
Regadenoson—Feeling abnormal—Gemcitabine—lung cancer	0.000184	0.000727	CcSEcCtD
Regadenoson—Shock—Paclitaxel—lung cancer	0.000184	0.000726	CcSEcCtD
Regadenoson—Dizziness—Vinorelbine—lung cancer	0.000184	0.000726	CcSEcCtD
Regadenoson—Nervous system disorder—Paclitaxel—lung cancer	0.000183	0.000724	CcSEcCtD
Regadenoson—Tachycardia—Paclitaxel—lung cancer	0.000183	0.00072	CcSEcCtD
Regadenoson—Skin disorder—Paclitaxel—lung cancer	0.000182	0.000717	CcSEcCtD
Regadenoson—Abdominal pain—Irinotecan—lung cancer	0.000181	0.000715	CcSEcCtD
Regadenoson—Hyperhidrosis—Paclitaxel—lung cancer	0.000181	0.000714	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Cisplatin—lung cancer	0.00018	0.000709	CcSEcCtD
Regadenoson—Hypotension—Etoposide—lung cancer	0.000178	0.000703	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GIPR—lung cancer	0.000178	0.0106	CbGpPWpGaD
Regadenoson—Pain—Cisplatin—lung cancer	0.000178	0.000703	CcSEcCtD
Regadenoson—Vomiting—Vinorelbine—lung cancer	0.000177	0.000698	CcSEcCtD
Regadenoson—Renal failure—Methotrexate—lung cancer	0.000176	0.000695	CcSEcCtD
Regadenoson—Rash—Vinorelbine—lung cancer	0.000175	0.000692	CcSEcCtD
Regadenoson—Dermatitis—Vinorelbine—lung cancer	0.000175	0.000691	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—lung cancer	0.000175	0.000691	CcSEcCtD
Regadenoson—Hypotension—Paclitaxel—lung cancer	0.000175	0.00069	CcSEcCtD
Regadenoson—Headache—Vinorelbine—lung cancer	0.000174	0.000688	CcSEcCtD
Regadenoson—Syncope—Docetaxel—lung cancer	0.000174	0.000687	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—lung cancer	0.000174	0.000687	CcSEcCtD
Regadenoson—Palpitations—Docetaxel—lung cancer	0.000172	0.000677	CcSEcCtD
Regadenoson—Feeling abnormal—Cisplatin—lung cancer	0.000172	0.000677	CcSEcCtD
Regadenoson—Paraesthesia—Etoposide—lung cancer	0.000171	0.000676	CcSEcCtD
Regadenoson—Loss of consciousness—Docetaxel—lung cancer	0.000171	0.000674	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.00017	0.000673	CcSEcCtD
Regadenoson—Dyspnoea—Etoposide—lung cancer	0.00017	0.000671	CcSEcCtD
Regadenoson—Somnolence—Etoposide—lung cancer	0.00017	0.000669	CcSEcCtD
Regadenoson—Cough—Docetaxel—lung cancer	0.00017	0.000669	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—lung cancer	0.00017	0.000669	CcSEcCtD
Regadenoson—Insomnia—Paclitaxel—lung cancer	0.000169	0.000668	CcSEcCtD
Regadenoson—Hypersensitivity—Irinotecan—lung cancer	0.000169	0.000667	CcSEcCtD
Regadenoson—Convulsion—Docetaxel—lung cancer	0.000168	0.000664	CcSEcCtD
Regadenoson—Paraesthesia—Paclitaxel—lung cancer	0.000168	0.000663	CcSEcCtD
Regadenoson—Hypertension—Docetaxel—lung cancer	0.000168	0.000662	CcSEcCtD
Regadenoson—Dyspnoea—Paclitaxel—lung cancer	0.000167	0.000658	CcSEcCtD
Regadenoson—Somnolence—Paclitaxel—lung cancer	0.000166	0.000656	CcSEcCtD
Regadenoson—Arthralgia—Docetaxel—lung cancer	0.000165	0.000653	CcSEcCtD
Regadenoson—Myalgia—Docetaxel—lung cancer	0.000165	0.000653	CcSEcCtD
Regadenoson—Chest pain—Docetaxel—lung cancer	0.000165	0.000653	CcSEcCtD
Regadenoson—Nausea—Vinorelbine—lung cancer	0.000165	0.000652	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Etoposide—lung cancer	0.000165	0.00065	CcSEcCtD
Regadenoson—Asthenia—Irinotecan—lung cancer	0.000165	0.000649	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000164	0.000648	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.000164	0.00977	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.000164	0.00977	CbGpPWpGaD
Regadenoson—Pain—Etoposide—lung cancer	0.000163	0.000644	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000162	0.000637	CcSEcCtD
Regadenoson—Asthenia—Gemcitabine—lung cancer	0.00016	0.000633	CcSEcCtD
Regadenoson—Pain—Paclitaxel—lung cancer	0.00016	0.000631	CcSEcCtD
Regadenoson—Anaphylactic shock—Docetaxel—lung cancer	0.000159	0.000626	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF9—lung cancer	0.000158	0.00945	CbGpPWpGaD
Regadenoson—Feeling abnormal—Etoposide—lung cancer	0.000157	0.00062	CcSEcCtD
Regadenoson—Diarrhoea—Irinotecan—lung cancer	0.000157	0.000619	CcSEcCtD
Regadenoson—Gastrointestinal pain—Etoposide—lung cancer	0.000156	0.000616	CcSEcCtD
Regadenoson—Shock—Docetaxel—lung cancer	0.000156	0.000616	CcSEcCtD
Regadenoson—Nervous system disorder—Docetaxel—lung cancer	0.000155	0.000614	CcSEcCtD
Regadenoson—Tachycardia—Docetaxel—lung cancer	0.000155	0.000611	CcSEcCtD
Regadenoson—Feeling abnormal—Paclitaxel—lung cancer	0.000154	0.000608	CcSEcCtD
Regadenoson—Skin disorder—Docetaxel—lung cancer	0.000154	0.000608	CcSEcCtD
Regadenoson—Hypersensitivity—Cisplatin—lung cancer	0.000153	0.000605	CcSEcCtD
Regadenoson—Gastrointestinal pain—Paclitaxel—lung cancer	0.000153	0.000604	CcSEcCtD
Regadenoson—Diarrhoea—Gemcitabine—lung cancer	0.000153	0.000603	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—lung cancer	0.000153	0.000602	CcSEcCtD
Regadenoson—Dizziness—Irinotecan—lung cancer	0.000152	0.000599	CcSEcCtD
Regadenoson—Urticaria—Etoposide—lung cancer	0.000152	0.000598	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GRM8—lung cancer	0.000151	0.00904	CbGpPWpGaD
Regadenoson—Abdominal pain—Etoposide—lung cancer	0.000151	0.000595	CcSEcCtD
Regadenoson—Eye disorder—Methotrexate—lung cancer	0.00015	0.000593	CcSEcCtD
Regadenoson—Tinnitus—Methotrexate—lung cancer	0.00015	0.000592	CcSEcCtD
Regadenoson—Asthenia—Cisplatin—lung cancer	0.000149	0.00059	CcSEcCtD
Regadenoson—Cardiac disorder—Methotrexate—lung cancer	0.000149	0.000589	CcSEcCtD
Regadenoson—Urticaria—Paclitaxel—lung cancer	0.000149	0.000586	CcSEcCtD
Regadenoson—Hypotension—Docetaxel—lung cancer	0.000148	0.000585	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ADCY1—lung cancer	0.000148	0.00884	CbGpPWpGaD
Regadenoson—Abdominal pain—Paclitaxel—lung cancer	0.000148	0.000584	CcSEcCtD
Regadenoson—Angiopathy—Methotrexate—lung cancer	0.000146	0.000576	CcSEcCtD
Regadenoson—Vomiting—Irinotecan—lung cancer	0.000146	0.000575	CcSEcCtD
Regadenoson—Immune system disorder—Methotrexate—lung cancer	0.000145	0.000573	CcSEcCtD
Regadenoson—Mediastinal disorder—Methotrexate—lung cancer	0.000145	0.000572	CcSEcCtD
Regadenoson—Rash—Irinotecan—lung cancer	0.000145	0.000571	CcSEcCtD
Regadenoson—Dermatitis—Irinotecan—lung cancer	0.000144	0.00057	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000144	0.00057	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PPP2R1B—lung cancer	0.000144	0.00861	CbGpPWpGaD
Regadenoson—Headache—Irinotecan—lung cancer	0.000144	0.000567	CcSEcCtD
Regadenoson—Insomnia—Docetaxel—lung cancer	0.000143	0.000566	CcSEcCtD
Regadenoson—Diarrhoea—Cisplatin—lung cancer	0.000142	0.000562	CcSEcCtD
Regadenoson—Paraesthesia—Docetaxel—lung cancer	0.000142	0.000562	CcSEcCtD
Regadenoson—Vomiting—Gemcitabine—lung cancer	0.000142	0.000561	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—lung cancer	0.000142	0.00056	CcSEcCtD
Regadenoson—Dyspnoea—Docetaxel—lung cancer	0.000141	0.000558	CcSEcCtD
Regadenoson—Somnolence—Docetaxel—lung cancer	0.000141	0.000556	CcSEcCtD
Regadenoson—Mental disorder—Methotrexate—lung cancer	0.000141	0.000556	CcSEcCtD
Regadenoson—Rash—Gemcitabine—lung cancer	0.000141	0.000556	CcSEcCtD
Regadenoson—Dermatitis—Gemcitabine—lung cancer	0.000141	0.000555	CcSEcCtD
Regadenoson—Hypersensitivity—Etoposide—lung cancer	0.000141	0.000555	CcSEcCtD
Regadenoson—Erythema—Methotrexate—lung cancer	0.00014	0.000553	CcSEcCtD
Regadenoson—Headache—Gemcitabine—lung cancer	0.00014	0.000552	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—lung cancer	0.000139	0.000547	CcSEcCtD
Regadenoson—Hypersensitivity—Paclitaxel—lung cancer	0.000138	0.000544	CcSEcCtD
Regadenoson—Dysgeusia—Methotrexate—lung cancer	0.000137	0.000541	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Docetaxel—lung cancer	0.000137	0.00054	CcSEcCtD
Regadenoson—Asthenia—Etoposide—lung cancer	0.000137	0.00054	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—lung cancer	0.000137	0.00054	CcSEcCtD
Regadenoson—Nausea—Irinotecan—lung cancer	0.000136	0.000538	CcSEcCtD
Regadenoson—Pain—Docetaxel—lung cancer	0.000136	0.000535	CcSEcCtD
Regadenoson—Asthenia—Paclitaxel—lung cancer	0.000134	0.00053	CcSEcCtD
Regadenoson—Nausea—Gemcitabine—lung cancer	0.000133	0.000524	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO3—lung cancer	0.000132	0.0079	CbGpPWpGaD
Regadenoson—Vomiting—Cisplatin—lung cancer	0.000132	0.000522	CcSEcCtD
Regadenoson—Vision blurred—Methotrexate—lung cancer	0.000132	0.000521	CcSEcCtD
Regadenoson—Rash—Cisplatin—lung cancer	0.000131	0.000518	CcSEcCtD
Regadenoson—Dermatitis—Cisplatin—lung cancer	0.000131	0.000518	CcSEcCtD
Regadenoson—Feeling abnormal—Docetaxel—lung cancer	0.000131	0.000516	CcSEcCtD
Regadenoson—Diarrhoea—Etoposide—lung cancer	0.000131	0.000515	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—lung cancer	0.00013	0.000514	CcSEcCtD
Regadenoson—Ill-defined disorder—Methotrexate—lung cancer	0.00013	0.000513	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—lung cancer	0.00013	0.000512	CcSEcCtD
Regadenoson—Gastrointestinal pain—Docetaxel—lung cancer	0.00013	0.000512	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—lung cancer	0.000129	0.00051	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—lung cancer	0.000129	0.00051	CcSEcCtD
Regadenoson—Diarrhoea—Paclitaxel—lung cancer	0.000128	0.000505	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—AVP—lung cancer	0.000127	0.00755	CbGpPWpGaD
Regadenoson—Angiopathy—Doxorubicin—lung cancer	0.000126	0.000499	CcSEcCtD
Regadenoson—Malaise—Methotrexate—lung cancer	0.000126	0.000498	CcSEcCtD
Regadenoson—Dizziness—Etoposide—lung cancer	0.000126	0.000498	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—lung cancer	0.000126	0.000496	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—lung cancer	0.000126	0.000495	CcSEcCtD
Regadenoson—Abdominal pain—Docetaxel—lung cancer	0.000125	0.000495	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—OXTR—lung cancer	0.000125	0.00744	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—GRP—lung cancer	0.000125	0.00744	CbGpPWpGaD
Regadenoson—ADORA2A—G alpha (s) signalling events—POMC—lung cancer	0.000124	0.00739	CbGpPWpGaD
Regadenoson—Dizziness—Paclitaxel—lung cancer	0.000124	0.000488	CcSEcCtD
Regadenoson—Nausea—Cisplatin—lung cancer	0.000124	0.000488	CcSEcCtD
Regadenoson—Cough—Methotrexate—lung cancer	0.000122	0.000482	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—lung cancer	0.000122	0.000482	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FGF9—lung cancer	0.000122	0.00726	CbGpPWpGaD
Regadenoson—Convulsion—Methotrexate—lung cancer	0.000121	0.000479	CcSEcCtD
Regadenoson—Vomiting—Etoposide—lung cancer	0.000121	0.000479	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—lung cancer	0.000121	0.000478	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00012	0.00719	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TYMS—lung cancer	0.00012	0.00718	CbGpPWpGaD
Regadenoson—Rash—Etoposide—lung cancer	0.00012	0.000475	CcSEcCtD
Regadenoson—Dermatitis—Etoposide—lung cancer	0.00012	0.000474	CcSEcCtD
Regadenoson—Headache—Etoposide—lung cancer	0.00012	0.000472	CcSEcCtD
Regadenoson—Myalgia—Methotrexate—lung cancer	0.000119	0.00047	CcSEcCtD
Regadenoson—Chest pain—Methotrexate—lung cancer	0.000119	0.00047	CcSEcCtD
Regadenoson—Arthralgia—Methotrexate—lung cancer	0.000119	0.00047	CcSEcCtD
Regadenoson—Vomiting—Paclitaxel—lung cancer	0.000119	0.000469	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—lung cancer	0.000119	0.000469	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000118	0.000467	CcSEcCtD
Regadenoson—Rash—Paclitaxel—lung cancer	0.000118	0.000465	CcSEcCtD
Regadenoson—Dermatitis—Paclitaxel—lung cancer	0.000118	0.000465	CcSEcCtD
Regadenoson—Discomfort—Methotrexate—lung cancer	0.000118	0.000465	CcSEcCtD
Regadenoson—Headache—Paclitaxel—lung cancer	0.000117	0.000462	CcSEcCtD
Regadenoson—Hypersensitivity—Docetaxel—lung cancer	0.000117	0.000461	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—GNG11—lung cancer	0.000117	0.00697	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Methotrexate—lung cancer	0.000114	0.000451	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—lung cancer	0.000114	0.000451	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.000114	0.00682	CbGpPWpGaD
Regadenoson—Asthenia—Docetaxel—lung cancer	0.000114	0.000449	CcSEcCtD
Regadenoson—Nausea—Etoposide—lung cancer	0.000113	0.000447	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—lung cancer	0.000113	0.000444	CcSEcCtD
Regadenoson—Nervous system disorder—Methotrexate—lung cancer	0.000112	0.000442	CcSEcCtD
Regadenoson—Nausea—Paclitaxel—lung cancer	0.000111	0.000438	CcSEcCtD
Regadenoson—Skin disorder—Methotrexate—lung cancer	0.000111	0.000438	CcSEcCtD
Regadenoson—Hyperhidrosis—Methotrexate—lung cancer	0.00011	0.000436	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—lung cancer	0.000109	0.000431	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—lung cancer	0.000109	0.000429	CcSEcCtD
Regadenoson—Diarrhoea—Docetaxel—lung cancer	0.000108	0.000428	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB3—lung cancer	0.000107	0.0064	CbGpPWpGaD
Regadenoson—Palpitations—Doxorubicin—lung cancer	0.000107	0.000423	CcSEcCtD
Regadenoson—Hypotension—Methotrexate—lung cancer	0.000107	0.000421	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—lung cancer	0.000107	0.000421	CcSEcCtD
Regadenoson—Cough—Doxorubicin—lung cancer	0.000106	0.000418	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—lung cancer	0.000105	0.000415	CcSEcCtD
Regadenoson—Dizziness—Docetaxel—lung cancer	0.000105	0.000414	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—lung cancer	0.000105	0.000413	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000104	0.000411	CcSEcCtD
Regadenoson—Insomnia—Methotrexate—lung cancer	0.000103	0.000408	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—lung cancer	0.000103	0.000407	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—lung cancer	0.000103	0.000407	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—lung cancer	0.000103	0.000407	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—lung cancer	0.000103	0.000406	CcSEcCtD
Regadenoson—Paraesthesia—Methotrexate—lung cancer	0.000103	0.000405	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000103	0.000405	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—lung cancer	0.000102	0.000402	CcSEcCtD
Regadenoson—Dyspnoea—Methotrexate—lung cancer	0.000102	0.000402	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FOXO3—lung cancer	0.000102	0.00608	CbGpPWpGaD
Regadenoson—Somnolence—Methotrexate—lung cancer	0.000102	0.000401	CcSEcCtD
Regadenoson—Vomiting—Docetaxel—lung cancer	0.000101	0.000398	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GIPR—lung cancer	0.000101	0.00601	CbGpPWpGaD
Regadenoson—Rash—Docetaxel—lung cancer	0.0001	0.000394	CcSEcCtD
Regadenoson—Dermatitis—Docetaxel—lung cancer	9.99e-05	0.000394	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR1—lung cancer	9.99e-05	0.00596	CbGpPWpGaD
Regadenoson—Headache—Docetaxel—lung cancer	9.93e-05	0.000392	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—lung cancer	9.9e-05	0.00039	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Methotrexate—lung cancer	9.87e-05	0.000389	CcSEcCtD
Regadenoson—Pain—Methotrexate—lung cancer	9.77e-05	0.000386	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—PTHLH—lung cancer	9.76e-05	0.00582	CbGpPWpGaD
Regadenoson—Shock—Doxorubicin—lung cancer	9.74e-05	0.000384	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—lung cancer	9.7e-05	0.000383	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—lung cancer	9.66e-05	0.000381	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—lung cancer	9.61e-05	0.000379	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—lung cancer	9.57e-05	0.000377	CcSEcCtD
Regadenoson—Nausea—Docetaxel—lung cancer	9.42e-05	0.000372	CcSEcCtD
Regadenoson—Feeling abnormal—Methotrexate—lung cancer	9.42e-05	0.000372	CcSEcCtD
Regadenoson—Gastrointestinal pain—Methotrexate—lung cancer	9.35e-05	0.000369	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—lung cancer	9.25e-05	0.000365	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—ANXA1—lung cancer	9.17e-05	0.00547	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GIPR—lung cancer	9.14e-05	0.00545	CbGpPWpGaD
Regadenoson—Urticaria—Methotrexate—lung cancer	9.08e-05	0.000358	CcSEcCtD
Regadenoson—Abdominal pain—Methotrexate—lung cancer	9.03e-05	0.000356	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—lung cancer	9.02e-05	0.000356	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—lung cancer	8.95e-05	0.000353	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—lung cancer	8.89e-05	0.000351	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	8.88e-05	0.0053	CbGpPWpGaD
Regadenoson—Dyspnoea—Doxorubicin—lung cancer	8.82e-05	0.000348	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—lung cancer	8.8e-05	0.000347	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—APP—lung cancer	8.7e-05	0.00519	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—lung cancer	8.67e-05	0.00517	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGF—lung cancer	8.57e-05	0.00511	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM8—lung cancer	8.56e-05	0.00511	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Doxorubicin—lung cancer	8.54e-05	0.000337	CcSEcCtD
Regadenoson—Pain—Doxorubicin—lung cancer	8.46e-05	0.000334	CcSEcCtD
Regadenoson—Adenosine triphosphate—ABCB1—lung cancer	8.44e-05	0.008	CrCbGaD
Regadenoson—Hypersensitivity—Methotrexate—lung cancer	8.42e-05	0.000332	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—ERBB3—lung cancer	8.25e-05	0.00492	CbGpPWpGaD
Regadenoson—Asthenia—Methotrexate—lung cancer	8.2e-05	0.000324	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—lung cancer	8.15e-05	0.000322	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—lung cancer	8.15e-05	0.00486	CbGpPWpGaD
Regadenoson—Gastrointestinal pain—Doxorubicin—lung cancer	8.09e-05	0.000319	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6R—lung cancer	8.05e-05	0.0048	CbGpPWpGaD
Regadenoson—Urticaria—Doxorubicin—lung cancer	7.86e-05	0.00031	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—lung cancer	7.82e-05	0.000309	CcSEcCtD
Regadenoson—Diarrhoea—Methotrexate—lung cancer	7.82e-05	0.000309	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRM8—lung cancer	7.77e-05	0.00464	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FGFR1—lung cancer	7.68e-05	0.00458	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAP2K1—lung cancer	7.67e-05	0.00458	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CD—lung cancer	7.62e-05	0.00455	CbGpPWpGaD
Regadenoson—Dizziness—Methotrexate—lung cancer	7.56e-05	0.000298	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—lung cancer	7.29e-05	0.000288	CcSEcCtD
Regadenoson—Vomiting—Methotrexate—lung cancer	7.27e-05	0.000287	CcSEcCtD
Regadenoson—Rash—Methotrexate—lung cancer	7.21e-05	0.000284	CcSEcCtD
Regadenoson—Dermatitis—Methotrexate—lung cancer	7.2e-05	0.000284	CcSEcCtD
Regadenoson—Headache—Methotrexate—lung cancer	7.16e-05	0.000283	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—AXL—lung cancer	7.12e-05	0.00425	CbGpPWpGaD
Regadenoson—Asthenia—Doxorubicin—lung cancer	7.1e-05	0.00028	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GRP—lung cancer	7.05e-05	0.00421	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—OXTR—lung cancer	7.05e-05	0.00421	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—lung cancer	6.82e-05	0.00407	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—RAF1—lung cancer	6.8e-05	0.00406	CbGpPWpGaD
Regadenoson—Nausea—Methotrexate—lung cancer	6.79e-05	0.000268	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—lung cancer	6.77e-05	0.000267	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—AVP—lung cancer	6.76e-05	0.00404	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—lung cancer	6.73e-05	0.00401	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KIT—lung cancer	6.67e-05	0.00398	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—lung cancer	6.64e-05	0.00396	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—lung cancer	6.64e-05	0.00396	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GNG11—lung cancer	6.6e-05	0.00394	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGF—lung cancer	6.59e-05	0.00393	CbGpPWpGaD
Regadenoson—Dizziness—Doxorubicin—lung cancer	6.54e-05	0.000258	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OXTR—lung cancer	6.4e-05	0.00382	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRP—lung cancer	6.4e-05	0.00382	CbGpPWpGaD
Regadenoson—Vomiting—Doxorubicin—lung cancer	6.29e-05	0.000248	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—BRAF—lung cancer	6.26e-05	0.00374	CbGpPWpGaD
Regadenoson—Rash—Doxorubicin—lung cancer	6.24e-05	0.000246	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—lung cancer	6.23e-05	0.000246	CcSEcCtD
Regadenoson—Headache—Doxorubicin—lung cancer	6.2e-05	0.000245	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—IL6R—lung cancer	6.19e-05	0.00369	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—lung cancer	6.05e-05	0.00361	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GNG11—lung cancer	5.99e-05	0.00357	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADCY1—lung cancer	5.93e-05	0.00354	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	5.9e-05	0.00352	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAP2K1—lung cancer	5.9e-05	0.00352	CbGpPWpGaD
Regadenoson—Nausea—Doxorubicin—lung cancer	5.88e-05	0.000232	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CD—lung cancer	5.86e-05	0.0035	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—PTEN—lung cancer	5.85e-05	0.00349	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—lung cancer	5.75e-05	0.00343	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—lung cancer	5.74e-05	0.00342	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—EP300—lung cancer	5.58e-05	0.00333	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—COL4A2—lung cancer	5.54e-05	0.00331	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PTHLH—lung cancer	5.51e-05	0.00329	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GIPR—lung cancer	5.4e-05	0.00322	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADCY1—lung cancer	5.39e-05	0.00321	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—lung cancer	5.32e-05	0.00318	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PPP2R1B—lung cancer	5.25e-05	0.00313	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MDM2—lung cancer	5.25e-05	0.00313	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—RAF1—lung cancer	5.23e-05	0.00312	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ANXA1—lung cancer	5.18e-05	0.00309	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—ERBB2—lung cancer	5.18e-05	0.00309	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—lung cancer	5.13e-05	0.00306	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—lung cancer	5.12e-05	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CB—lung cancer	5.11e-05	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—lung cancer	5.11e-05	0.00305	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SDC4—lung cancer	5.04e-05	0.00301	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PTHLH—lung cancer	5.01e-05	0.00299	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DUSP3—lung cancer	4.94e-05	0.00295	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—APP—lung cancer	4.92e-05	0.00293	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MAPK3—lung cancer	4.9e-05	0.00293	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RHEB—lung cancer	4.84e-05	0.00289	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ANXA1—lung cancer	4.71e-05	0.00281	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—lung cancer	4.7e-05	0.0028	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—lung cancer	4.66e-05	0.00278	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM8—lung cancer	4.59e-05	0.00274	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	4.57e-05	0.00272	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—lung cancer	4.49e-05	0.00268	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—APP—lung cancer	4.46e-05	0.00266	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SKI—lung cancer	4.45e-05	0.00265	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—CDKN1A—lung cancer	4.42e-05	0.00264	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PTEN—lung cancer	4.41e-05	0.00263	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—lung cancer	4.41e-05	0.00263	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—SRC—lung cancer	4.09e-05	0.00244	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—lung cancer	4.05e-05	0.00242	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—TP53—lung cancer	3.99e-05	0.00238	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—STAT3—lung cancer	3.95e-05	0.00236	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NRAS—lung cancer	3.94e-05	0.00235	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PXN—lung cancer	3.86e-05	0.0023	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AVP—lung cancer	3.82e-05	0.00228	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRP—lung cancer	3.78e-05	0.00226	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKR1C1—lung cancer	3.78e-05	0.00226	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OXTR—lung cancer	3.78e-05	0.00226	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MAPK3—lung cancer	3.77e-05	0.00225	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—lung cancer	3.75e-05	0.00223	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—IL6—lung cancer	3.66e-05	0.00218	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—EGFR—lung cancer	3.59e-05	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—lung cancer	3.58e-05	0.00214	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GNG11—lung cancer	3.54e-05	0.00211	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL8—lung cancer	3.48e-05	0.00207	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AVP—lung cancer	3.47e-05	0.00207	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—KRAS—lung cancer	3.39e-05	0.00202	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFC—lung cancer	3.37e-05	0.00201	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—lung cancer	3.31e-05	0.00197	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADCY1—lung cancer	3.18e-05	0.0019	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—PIK3CA—lung cancer	3.11e-05	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PPP2R1B—lung cancer	3.1e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SMARCA4—lung cancer	3.1e-05	0.00185	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSPB1—lung cancer	2.99e-05	0.00179	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTHLH—lung cancer	2.96e-05	0.00177	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HRAS—lung cancer	2.88e-05	0.00172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ANXA1—lung cancer	2.78e-05	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—IL6—lung cancer	2.76e-05	0.00164	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FLT1—lung cancer	2.69e-05	0.00161	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CG—lung cancer	2.67e-05	0.00159	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APP—lung cancer	2.64e-05	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NOTCH3—lung cancer	2.64e-05	0.00157	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF9—lung cancer	2.62e-05	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—lung cancer	2.54e-05	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—lung cancer	2.54e-05	0.00152	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUNB—lung cancer	2.5e-05	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CG—lung cancer	2.42e-05	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CD—lung cancer	2.35e-05	0.0014	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—lung cancer	2.31e-05	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STK11—lung cancer	2.27e-05	0.00135	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6R—lung cancer	2.25e-05	0.00134	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FOXO3—lung cancer	2.19e-05	0.00131	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAP2K1—lung cancer	2.14e-05	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CD—lung cancer	2.13e-05	0.00127	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AVP—lung cancer	2.05e-05	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CB—lung cancer	2.04e-05	0.00122	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IGF1R—lung cancer	1.97e-05	0.00118	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL8—lung cancer	1.96e-05	0.00117	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HES1—lung cancer	1.94e-05	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—RAF1—lung cancer	1.9e-05	0.00113	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—IL2—lung cancer	1.88e-05	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CB—lung cancer	1.86e-05	0.00111	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL8—lung cancer	1.78e-05	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB3—lung cancer	1.77e-05	0.00106	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL2—lung cancer	1.71e-05	0.00102	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TERT—lung cancer	1.7e-05	0.00101	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGFR1—lung cancer	1.65e-05	0.000984	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HIF1A—lung cancer	1.62e-05	0.00097	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOA1—lung cancer	1.57e-05	0.000936	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—lung cancer	1.55e-05	0.000927	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KIT—lung cancer	1.43e-05	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APC—lung cancer	1.43e-05	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CG—lung cancer	1.43e-05	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NRAS—lung cancer	1.43e-05	0.000854	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGF—lung cancer	1.42e-05	0.000844	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—MAPK3—lung cancer	1.37e-05	0.000818	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—lung cancer	1.36e-05	0.000813	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BRAF—lung cancer	1.35e-05	0.000803	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6R—lung cancer	1.33e-05	0.000793	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CREBBP—lung cancer	1.33e-05	0.000792	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—EGFR—lung cancer	1.3e-05	0.000778	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAP2K1—lung cancer	1.27e-05	0.000756	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CD—lung cancer	1.26e-05	0.000751	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PIK3CA—lung cancer	1.25e-05	0.000744	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—KRAS—lung cancer	1.23e-05	0.000735	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PIK3CA—lung cancer	1.13e-05	0.000675	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MDM2—lung cancer	1.13e-05	0.000673	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RAF1—lung cancer	1.12e-05	0.00067	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ERBB2—lung cancer	1.11e-05	0.000663	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—lung cancer	1.1e-05	0.000655	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CB—lung cancer	1.1e-05	0.000655	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL8—lung cancer	1.05e-05	0.000629	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—HRAS—lung cancer	1.05e-05	0.000625	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—lung cancer	1.02e-05	0.000608	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—lung cancer	1.01e-05	0.000602	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL2—lung cancer	1.01e-05	0.000601	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6—lung cancer	1e-05	0.000598	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCND1—lung cancer	9.82e-06	0.000586	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—lung cancer	9.8e-06	0.000585	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—lung cancer	9.53e-06	0.000569	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDKN1A—lung cancer	9.5e-06	0.000567	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTEN—lung cancer	9.48e-06	0.000566	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—lung cancer	9.25e-06	0.000552	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EP300—lung cancer	9.04e-06	0.000539	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—lung cancer	8.79e-06	0.000525	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—lung cancer	8.56e-06	0.000511	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—STAT3—lung cancer	8.48e-06	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NRAS—lung cancer	8.46e-06	0.000505	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MAPK3—lung cancer	8.1e-06	0.000483	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MYC—lung cancer	7.88e-06	0.00047	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—EGFR—lung cancer	7.7e-06	0.00046	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KRAS—lung cancer	7.28e-06	0.000434	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PIK3CA—lung cancer	6.69e-06	0.000399	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TP53—lung cancer	6.47e-06	0.000386	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HRAS—lung cancer	6.19e-06	0.000369	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6—lung cancer	5.92e-06	0.000353	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—lung cancer	5.46e-06	0.000326	CbGpPWpGaD
